Home arrow Articles arrow New treatment for rabies advances after successful phase 1 trial in India
New treatment for rabies advances after successful phase 1 trial in India Print E-mail
User Rating: / 0
PoorBest 
Post by Administrator   
ѹ, 20 ѹ¹ 2010

BOSTON, Mass.—With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

Details of the study were reported on September 14 at the American Society for Microbiology's 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston, Massachusetts in a poster presentation titled, "A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study," by researchers from MassBiologics; the Serum Institute of India in Pune, India; and King Edward Memorial Hospital (KEM) in Mumbai, India.

"We are very encouraged by the results from this trial," said Donna Ambrosino, MD, executive director of MassBiologics and a professor of pediatrics at the Medical School.

 

more information PDF download

Last Updated ( ҷԵ, 19 ѹ¹ 2010 )
< Previous   Next >

»СѹԵ
ʹ

Login